Tenaya Therapeutics (NASDAQ:TNYA) Stock Rating Lowered by Wall Street Zen

Tenaya Therapeutics (NASDAQ:TNYA) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings upgraded shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Tenaya Therapeutics Price Performance

NASDAQ TNYA opened at $0.69 on Friday. The stock has a market capitalization of $154.74 million, a P/E ratio of -1.30 and a beta of 2.83. The business has a 50 day simple moving average of $0.76 and a 200 day simple moving average of $0.75. Tenaya Therapeutics has a one year low of $0.53 and a one year high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.13). The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $10.00 million. Equities analysts expect that Tenaya Therapeutics will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TNYA. Integrity Wealth Solutions LLC bought a new stake in shares of Tenaya Therapeutics during the first quarter worth about $27,000. Scientech Research LLC acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter worth about $27,000. Callan Family Office LLC bought a new position in Tenaya Therapeutics in the 2nd quarter valued at about $37,000. Comerica Bank bought a new position in Tenaya Therapeutics in the 1st quarter valued at about $50,000. Finally, Cerity Partners LLC boosted its stake in Tenaya Therapeutics by 403.5% during the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock valued at $67,000 after purchasing an additional 88,424 shares during the last quarter. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.